John M Leonard
CIK 1563584 · President and CEO · last filed 2026-08-24
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
NTLA price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
40 ERIE STREET, SUITE 130
CAMBRIDGE, MA 02139
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| NTLA | President and CEO | 1,208,264 | $11.21 | $13.54M | -$54.97M | 39 | 2026-08-24 |
| IQV | Director | 16,946 | $275.72 | $4.67M | -$3.09M | 10 | 2026-04-27 |
| CHIMERIX INC (CMRX) Delisted | Director | 4,000 | $8.54 | $34.2K | $138.2K | 6 | 2017-06-29 |
| Q | Director | 4,702 | $109.86 | $516.6K | $0 | 4 | 2017-05-25 |
| Vitae Pharmaceuticals, Inc (VTAE) Delisted | Director | — | — | — | $0 | 3 | 2016-10-25 |
| ABBV | SVP, Chief Scientific Officer | 113,793 | $284.04 | $32.32M | -$2.84M | 5 | 2013-03-19 |
Recent Filings · Page 6 of 7
69 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2017-06-05 | NTLA | Grant (A) | +8,400 | $101.3K | EDGAR |
| 2017-05-25 | Q | Grant (A) | +2,386 | $0 | EDGAR |
| 2017-01-10 | NTLA | Grant (A) | — | $0 | EDGAR |
| 2016-10-25 | Vitae Pharmaceuticals, Inc (VTAE) Delisted | Disp (D) | — | $0 | EDGAR |
| 2016-09-16 | CHIMERIX INC (CMRX) Delisted | Sell (S) | −5,000 | -$25.2K | EDGAR |
| 2016-06-28 | CHIMERIX INC (CMRX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2016-05-27 | Vitae Pharmaceuticals, Inc (VTAE) Delisted | Grant (A) | — | $0 | EDGAR |
| 2016-05-06 | Q | Grant (A) | +775 | $0 | EDGAR |
| 2015-08-25 | CHIMERIX INC (CMRX) Delisted | Buy (P) | +1,000 | $47.4K | EDGAR |
| 2015-07-29 | Vitae Pharmaceuticals, Inc (VTAE) Delisted | Grant (A) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.